Scarica l'app Stockscreener
12.90
2.30%
0.29
Precedente Chiudi:
$12.61
Aprire:
$12.73
Volume 24 ore:
1.95M
Relative Volume:
1.38
Capitalizzazione di mercato:
$762.58M
Reddito:
$122.29M
Utile/perdita netta:
$122.31M
Rapporto P/E:
5.9891
EPS:
2.1539
Flusso di cassa netto:
$12.00M
1 W Prestazione:
-0.54%
1M Prestazione:
+23.68%
6M Prestazione:
+59.26%
1 anno Prestazione:
+42.23%
Intervallo 1D:
$12.67
$13.07
Intervallo di 1 settimana:
$12.18
$13.74
Portata 52W:
$7.16
$14.27
Zevra Therapeutics Inc Stock (ZVRA) Company Profile
Nome
Zevra Therapeutics Inc
Settore
Industria
Telefono
(888) 958-1253
Indirizzo
101 FEDERAL STREET, BOSTON
Compare ZVRA vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ZVRA
Zevra Therapeutics Inc
|
12.90 | 762.58M | 122.29M | 122.31M | 12.00M | 2.1539 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-16 | Iniziato | BTIG Research | Buy |
| 2025-07-02 | Iniziato | H.C. Wainwright | Buy |
| 2025-01-08 | Ripresa | Cantor Fitzgerald | Overweight |
| 2024-10-07 | Iniziato | Guggenheim | Buy |
| 2024-09-24 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-09-24 | Reiterato | Maxim Group | Buy |
| 2024-04-02 | Reiterato | Maxim Group | Buy |
| 2024-03-12 | Iniziato | William Blair | Outperform |
| 2023-03-17 | Iniziato | Maxim Group | Buy |
Mostra tutto
Zevra Therapeutics Inc Borsa (ZVRA) Ultime notizie
Director at Zevra Therapeutics (ZVRA) granted 30,000 stock options - Stock Titan
Board member at Zevra (NASDAQ: ZVRA) receives 30,000-share option grant - Stock Titan
Zevra Therapeutics (ZVRA) awards director 30,000 stock options - Stock Titan
Zevra Therapeutics (ZVRA) director awarded 30,000 options at $11.17 strike - Stock Titan
Zevra Therapeutics (NASDAQ: ZVRA) director gets 30,000 stock options grant - Stock Titan
Zevra Therapeutics (ZVRA) director awarded 30,000 stock options at set price - Stock Titan
Zevra Therapeutics Inc (ZVRA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Zevra Therapeutics Inc (ZVRA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Zevra Therapeutics Inc (ZVRA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Zevra Therapeutics Inc (ZVRA) Institutional Confidence - TradingKey
Zevra Therapeutics Inc (ZVRA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Zevra Therapeutics Inc (ZVRA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Zevra Therapeutics Inc (ZVRA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Zevra Therapeutics Inc (ZVRA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Zevra Therapeutics Inc (ZVRA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ZVRA Stock Hits Its Highest Levels In Nearly 5 Years – What’s Driving This Sharp Rally Today? - Stocktwits
ZVRA Price Today: Zevra Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Zevra Therapeutics Q2 2025 Earnings Preview - MSN
symbol__ Stock Quote Price and Forecast - CNN
ZVRA News | ZEVRA THERAPEUTICS INC (NASDAQ:ZVRA) - ChartMill
ZVRA Maintained by Canaccord Genuity -- Price Target Stays at $2 - GuruFocus
Zevra Therapeutics Is Maintained at Buy by Canaccord Genuity - Moomoo
A Quick Look at Today's Ratings for Zevra Therapeutics(ZVRA.US), With a Forecast Between $25 to $29 - Moomoo
Zevra’s Chief Medical Officer to Step Down for Personal Reasons as Part of Planned Transition - The Manila Times
Press Release: Zevra's Chief Medical Officer to Step Down for Personal Reasons as Part of Planned Transition - Moomoo
ZVRA Upgraded by Guggenheim -- Price Target Raised to $29 - GuruFocus
ZVRA Maintains Rating by Maxim Group -- Price Target Raised to $35.00 - GuruFocus
A Quick Look at Today's Ratings for Zevra Therapeutics(ZVRA.US), With a Forecast Between $25 to $34 - Moomoo
Zevra Therapeutics Is Maintained at Buy by Maxim Group - Moomoo
Maxim Group Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Raises Target Price to $35 - Moomoo
Guggenheim raises Zevra Therapeutics price target on patent extension - Investing.com UK
Guggenheim raises Zevra Therapeutics price target on patent extension By Investing.com - Investing.com Nigeria
ZVRA Reiterates by BTIG -- Price Target Raised to $27.00 - GuruFocus
Liquidity Mapping Around (ZVRA) Price Events - Stock Traders Daily
Is Zevra Therapeutics (ZVRA) Using MIPLYFFA Patent Extensions To Deepen Its Rare-Disease Moat? - Yahoo Finance
H.C. Wainwright reiterates Zevra Therapeutics stock rating on patent extension - Investing.com Australia
BTIG raises Zevra Therapeutics price target to $27 on patent filing - Investing.com Nigeria
ZVRA Maintains Buy Rating -- Price Target Raised to $29.00 by Ca - GuruFocus
BTIG raises Zevra Therapeutics price target to $27 on patent filing By Investing.com - Investing.com India
ZVRA stock hits its highest levels in nearly 5 years – what’s driving this sharp rally today? - MSN
ZVRA Maintains by Citizens -- Price Target Raised to $25.00 - GuruFocus
Zevra Therapeutics stock price target raised to $29 by Canaccord on patent extension - Investing.com South Africa
H.C. Wainwright reiterates Zevra Therapeutics stock rating on patent extension By Investing.com - Investing.com South Africa
Citizens raises Zevra Therapeutics price target on patent exclusivity By Investing.com - Investing.com Nigeria
Citizens raises Zevra Therapeutics price target on patent exclusivity - Investing.com
Zevra Therapeutics Inc Azioni (ZVRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.74%
1.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):